Goldman Sachs
ENGN icon

Goldman Sachs’s enGene Therapeutics ENGN Stock Holding History

Goldman Sachs’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-147,889
Closed -$1.34M – 6625
2025
Q4 		$1.34M Buy
147,889
+287
+0.2% +$2.3K ﹤0.01% 4906
2025
Q3 		$1.01M Sell
147,602
-751,484
-84% -$3.43M ﹤0.01% 5010
2025
Q2 		$3.27M Hold
899,086
– – ﹤0.01% 3808
2025
Q1 		$4.03M Hold
899,086
– – ﹤0.01% 3566
2024
Q4 		$5.98M Buy
+899,086
New +$6.98M ﹤0.01% 3276
2024
Q1 		– Sell
-37,447
Closed -$346K – 5632
2023
Q4 		$346K Buy
+37,447
New +$331K ﹤0.01% 4926

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Goldman Sachs's ENGN Position: Q1 2026 in Review

Goldman Sachs sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 147,889 shares — an estimated $1.34M sold.

Goldman Sachs first reported a position in ENGN in Q4 2023 and held it in 6 quarters. The position peaked at $5.98M in Q4 2024. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Goldman Sachs reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 147,889 enGene Therapeutics shares in Q1 2026, an estimated $1.34M.
  • Goldman Sachs first reported a position in enGene Therapeutics in Q4 2023 and held it in 6 quarters.
  • Goldman Sachs's enGene Therapeutics position peaked at $5.98M in Q4 2024.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.